SARS-CoV-2 variants from mink evade inhibition by antibodies

It has been known for about a year that minks can become infected with SARS-CoV-2. The virus had been transmitted from humans to farmed mink and mutated in infected animals. Mutations were acquired in the spike protein, which is crucial for the entry of the virus into host cells and represents the central point of attack for antibodies. These SARS-CoV-2 variants from mink were transmitted back to humans, raising concerns that minks could be a continuing source of infection of humans with SARS-CoV-2 variants with altered biological properties. Researchers at the German Primate Center (DPZ) - Leibniz Institute for Primate Research in Göttingen, Germany, have now shown that an antibody used for COVID-19 therapy is unable to effectively inhibit SARS-CoV-2 harboring a spike mutation acquired in minks. In addition, the mutation reduced the inhibition of the virus by antibodies produced in SARS-CoV-2 infected humans. These results show that SARS-CoV-2 can acquire mutations in minks that may reduce control of the virus by the human immune system. The study and findings have been published in Cell Reports.

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS -CoV-2

Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy

Mutations arising in SARS-CoV-2 spike on sustained human-to-human transmission and human-to-animal passage - SARS-CoV-2 coronavirus - Virological

Enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants BA.4 and BA.5

Viruses, Free Full-Text

Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern

Viruses, Free Full-Text

SARS-CoV-2 escape mutations identified against monoclonal antibodies and polyclonal immune sera

Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines